Literature DB >> 36267821

Cancer patients and targeted therapy during COVID-19 pandemic: A descriptive case series study.

Kasra Khodadadi1, Minoosh Moghimi2, Reza Mansouri2.   

Abstract

To evaluate the effectiveness of targeted therapy on preventing or treating COVID-19, in this study, we want to share our experience about 14 patients (nine women, five men; average age, 59 years) who were treated with targeted therapy due to their underlying malignant disorders in our center.
© 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.

Entities:  

Keywords:  COVID‐19; case series; immunotherapy; malignant disease; targeted therapy

Year:  2022        PMID： 36267821      PMCID： PMC9576967          DOI： 10.1002/ccr3.6392

Source DB:  PubMed          Journal:  Clin Case Rep        ISSN： 2050-0904


  25 in total

1.  'A recurrent cutaneous eruption'.

Authors:  Navin Kumar Devaraj
Journal:  BMJ Case Rep       Date:  2019-02-01

2.  Antibiotic Resistance: A Real Menace.

Authors:  Navin Kumar Devaraj
Journal:  Oman Med J       Date:  2017-11

3.  Ruxolitinib: in the treatment of myelofibrosis.

Authors:  Lily P H Yang; Gillian M Keating
Journal:  Drugs       Date:  2012-11-12       Impact factor: 9.546

4.  Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

Authors:  John C Byrd; Jennifer R Brown; Susan O'Brien; Jacqueline C Barrientos; Neil E Kay; Nishitha M Reddy; Steven Coutre; Constantine S Tam; Stephen P Mulligan; Ulrich Jaeger; Steve Devereux; Paul M Barr; Richard R Furman; Thomas J Kipps; Florence Cymbalista; Christopher Pocock; Patrick Thornton; Federico Caligaris-Cappio; Tadeusz Robak; Julio Delgado; Stephen J Schuster; Marco Montillo; Anna Schuh; Sven de Vos; Devinder Gill; Adrian Bloor; Claire Dearden; Carol Moreno; Jeffrey J Jones; Alvina D Chu; Maria Fardis; Jesse McGreivy; Fong Clow; Danelle F James; Peter Hillmen
Journal:  N Engl J Med       Date:  2014-05-31       Impact factor: 91.245

5.  Viral acute lower respiratory infections impair CD8+ T cells through PD-1.

Authors:  John J Erickson; Pavlo Gilchuk; Andrew K Hastings; Sharon J Tollefson; Monika Johnson; Melissa B Downing; Kelli L Boyd; Joyce E Johnson; Annette S Kim; Sebastian Joyce; John V Williams
Journal:  J Clin Invest       Date:  2012-07-17       Impact factor: 14.808

6.  Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.

Authors:  Susan O'Brien; Richard R Furman; Steven Coutre; Ian W Flinn; Jan A Burger; Kristie Blum; Jeff Sharman; William Wierda; Jeffrey Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Ying Luan; Danelle F James; Alvina D Chu; John C Byrd
Journal:  Blood       Date:  2018-02-02       Impact factor: 25.476

7.  Ibrutinib for chronic lymphocytic leukemia in the setting of respiratory failure from severe COVID-19 infection: Case report and literature review.

Authors:  Adam Yuh Lin; Michael J Cuttica; Michael G Ison; Leo I Gordon
Journal:  EJHaem       Date:  2020-09-20

8.  Btk regulates macrophage polarization in response to lipopolysaccharide.

Authors:  Joan Ní Gabhann; Emily Hams; Siobhán Smith; Claire Wynne; Jennifer C Byrne; Kiva Brennan; Shaun Spence; Adrien Kissenpfennig; James A Johnston; Padraic G Fallon; Caroline A Jefferies
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

9.  Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China.

Authors:  L Zhang; F Zhu; L Xie; C Wang; J Wang; R Chen; P Jia; H Q Guan; L Peng; Y Chen; P Peng; P Zhang; Q Chu; Q Shen; Y Wang; S Y Xu; J P Zhao; M Zhou
Journal:  Ann Oncol       Date:  2020-03-26       Impact factor: 32.976

10.  COVID-19: combining antiviral and anti-inflammatory treatments.

Authors:  Justin Stebbing; Anne Phelan; Ivan Griffin; Catherine Tucker; Olly Oechsle; Dan Smith; Peter Richardson
Journal:  Lancet Infect Dis       Date:  2020-02-27       Impact factor: 25.071
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.